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The world is facing an under-supply of some key vaccines due to poor synergies between growing market 
demands and aging production models.  
 
In this light, we have developed a proof of concept of a vaccine manufacturing platform aiming at increasing 
availability and affordability of vaccines - the NevoLineTM system. 
 
This simulated continuous and automated platform integrates both USP1 and DSP2 processes and is 
encapsulated into an isolator, making it a self-contained production unit (6m²). 
The technology relies on a single-use, high-density fixed-bed bioreactor operated in perfusion chained with 
downstream filtration, clarification and polishing steps to (a) decrease batch time, (b) reduce equipment 
utilization, (c) optimize utilities consumption and (d) intensify operations. By optimizing single-use technologies 
we are able to drastically reduce CAPEX3, CoGs4 and footprint and increase production capacity. Such 
manufacturing platform can easily be implemented into flexible facilities with simplified infrastructure, increasing 
adaptability in production and capacity for record time-to-market. 
 
This study will present the platform proof of concept on Vero line and trivalent inactivated polio vaccine (sIPV) 
production, achieving low CoGs (0,28$/dose for a trivalent sIPV) and large capacity. The presentation will 
feature the description of engineering development, but also results of cell growth, infections and product 
quality, as well as a description of the CAPEX, CoGS and capacity calculations. This manufacturing platform is 
undergoing sIPV process scale-up and pre-clinical bulk production. 
 
The NevoLine system is expected to produce any type of viral vaccine at a very low cost and large capacities to 
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